Provided by Tiger Fintech (Singapore) Pte. Ltd.

Prelude Therapeutics Inc

0.7360
+0.02393.36%
Volume:81.67K
Turnover:60.46K
Market Cap:40.51M
PE:-0.42
High:0.7631
Open:0.7120
Low:0.7120
Close:0.7121
Loading ...

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

GlobeNewswire
·
05 Mar

Prelude Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview

Reuters
·
11 Feb

BRIEF-Prelude Therapeutics Names Bryant Lim As Permanent CFO

Reuters
·
06 Feb

Prelude Therapeutics Appoints Bryant D. Lim as CFO

TIPRANKS
·
06 Feb

Prelude Therapeutics Inc - Appoints Bryant D. Lim as Permanent CFO

THOMSON REUTERS
·
06 Feb

Krishna Vaddi Bought 4.9% More Shares In Prelude Therapeutics

Simply Wall St.
·
22 Dec 2024

Prelude Therapeutics (PRLD) Gets a Sell from Morgan Stanley

TIPRANKS
·
12 Dec 2024

BRIEF-Prelude Therapeutics Presents Preliminary Results Of Phase 1 Dose-Escalation Study Of PRT2527 As Monotherapy And In Combination With Zanubrutinib

Reuters
·
11 Dec 2024

Prelude Therapeutics presents first interim data from trial of PRT2527

TIPRANKS
·
11 Dec 2024

Prelude Therapeutics Inc: Plans to Seek a Partner for Future Development of PRT2527 in Hematologic Malignancies

THOMSON REUTERS
·
11 Dec 2024

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-Escalation Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Patients With Relapsed/Refractory Lymphoid Malignancies

THOMSON REUTERS
·
11 Dec 2024

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

GlobeNewswire
·
11 Dec 2024

Prelude Therapeutics price target lowered to $4 from $7 at JMP Securities

TIPRANKS
·
11 Dec 2024

Prelude Therapeutics: Promising Clinical Advancements and Strong Financial Position Drive Buy Rating

TIPRANKS
·
11 Dec 2024

November 2024's Top Picks: Penny Stocks On US Exchanges

Simply Wall St.
·
30 Nov 2024

After Plunging -31.47% in 4 Weeks, Here's Why the Trend Might Reverse for Prelude Therapeutics (PRLD)

Zacks
·
27 Nov 2024